Nirav Shah to Pyrimidines
This is a "connection" page, showing publications Nirav Shah has written about Pyrimidines.
Connection Strength
0.499
-
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197.
Score: 0.181
-
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 11; 93(11):1394-1401.
Score: 0.122
-
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
Score: 0.046
-
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
Score: 0.046
-
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
Score: 0.036
-
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 05 14; 135(20):1739-1749.
Score: 0.034
-
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 05; 26(5):893-901.
Score: 0.033